Email Alert RSS
Volume 14 Issue 5
Sep.  2023
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2023  >  14(5): 999-1004
WU Yun, CHEN Jiawei, WANG Tong, LI Jin, ZHANG Ge, KANG Wei, ZHANG Jingjia, SUN Hongli, XU Yingchun, LIU Yali. In Vitro Activity of Sixteen Drugs Against Staphylococcus Aureus, Enterococcus Faecalis and Enterococcus Faecium: A Multicentre Cross-sectional Study in China[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 999-1004. doi: 10.12290/xhyxzz.2023-0070
Citation: WU Yun, CHEN Jiawei, WANG Tong, LI Jin, ZHANG Ge, KANG Wei, ZHANG Jingjia, SUN Hongli, XU Yingchun, LIU Yali. In Vitro Activity of Sixteen Drugs Against Staphylococcus Aureus, Enterococcus Faecalis and Enterococcus Faecium: A Multicentre Cross-sectional Study in China[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 999-1004. doi: 10.12290/xhyxzz.2023-0070
shu

In Vitro Activity of Sixteen Drugs Against Staphylococcus Aureus, Enterococcus Faecalis and Enterococcus Faecium: A Multicentre Cross-sectional Study in China

doi: 10.12290/xhyxzz.2023-0070
  • 1.

    Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 2.

    Graduate School, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds:

Special Foundation for National Science and Technology Basic Research Program of China: Establishment of A Standardised Stratified Surveillance System for Infectious Pathogens and Investigation of Drug Susceptibility and Resistance in China 2019FY101200

More Information
  • Corresponding author: XU Yingchun, E-mail: xycpumch@139.com; LIU Yali, E-mail: liuyluijk@163.com
  • Received Date: 2023-02-10
  • Accepted Date: 2023-05-09
  • Publish Date: 2023-09-30
    Abstract
  •   Objective  To evaluate the in vitro antimicrobial activities of 16 common agents against Staphylococcus aureus, Enterococcus faecium and Enterococcus faecalis to provide data for the rational clinical use of drugs.  Methods  From 1st January to 31st December in 2019, Staphylococcus aureus, Enterococcus faecium and Enterococcus faecalis were collected from 24 hospitals in 18 provinces in China. Antimicrobial susceptibility testing was conducted by automated instrumentation method, and WHONET 5.6 software was used to calculate the drug sensitivity results of the strains to 16 antibacterial drugs including vancomycin, norvancomycin, fusidic acid and linezolid.  Results  A total of 255 strains of Staphylococcus aureus, 117 strains of Enterococcus faecalis and 114 strains of Enterococcus faecium were collected. Blood was the most common specimen type (22.2%, 108/486), followed by urine (18.9%, 82/486). According to the drug sensitivity results, vancomycin, norvancomycin, linezolid and teicoplanin maintained high activity to all strains. All Staphylococcus aureus and Enterococcus faecalis were sensitive to vancomycin and teicoplanin, while the resistance rates of vancomycin and teicoplanin against Enterococcus faecium were 4.4% and 2.6%, respectively. The resistance rates of linezolid against Staphylococcus aureus, Eenterococcus faecium and Eenterococcus fascalis were 0, 0 and 4.3%, respectively. Norvancomycin and vancomycin showed similar antibacterial activity against Staphylococcus aureus, Enterococcus faecium, and Enterococcus faecalis, with 50% minimum inhibitory concentration (MIC50) of 1 mg/L, and MIC90 of 2 mg/L. The isolation rate of methicillin-resistant Staphylococcus aureas(MRSA) was 35.7%, with 13.2% resistance to fusidic acid and 3.0% in methicillin-susceptible Staphylococcus aureas.  Conclusions  The activity of the 16 antimicro-bial drugs against Staphylococcus aureus, Enterococcus faecium and Enterococcus faecalis varied considerably. The data will provide reference for the rational use of antimicrobial drugs.
    • FullText(HTML)
  • loading
    • References(15)
  • [1] Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens[J]. Expert Rev Anti Infect Ther, 2013, 11: 297-308. doi:  10.1586/eri.13.12
    [2] Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. 33rd ed. CLSI document M100. Wayne, PA: CLSI, 2023.
    [3] European Committee on Antimicrobial Susceptibility Testing. EUCAST clinical breakpoint table [EB/OL]. [2023-02-10]. https://www.eucast.org/clinical_breakpoints/.
    [4] Arias CA, Murray BE. Emergence and management of drug-resistant enterococcal infections[J]. Expert Rev Anti Infect Ther, 2008, 6: 637-55. doi:  10.1586/14787210.6.5.637
    [5] CHINET中国细菌耐药监测网.CHINET中国细菌耐药检测结果(2022年1—12月)[EB/OL ].(2022-09)[2023-07-03]. https://max.book118.com/html/2022/0913/6213051034004235.shtm.
    [6] Ding L, Yang Y, Zheng C, et al. Activities of Eravacycline, Tedizolid, Norvancomycin, Nemonoxacin, Ceftaroline, and Comparators against 1, 871 Staphylococcus and 1, 068 Enterococcus Species Isolates from China: Updated Report of the CHINET Study 2019 [J]. Microbiol Spectr, 2022, 10: e0171522. doi:  10.1128/spectrum.01715-22
    [7] Shariati A, Dadashi M, Chegini Z, et al. The global prevalence of Daptomycin, Tigecycline, Quinupristin/Dalfopri-stin, and Linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-analysis. Antimicrob Resist Infect Control [J]. Antimicrob Resist Infect Control, 2020, 9: 56.
    [8] Schöfer H, Simonsen L. Fusidic acid in dermatology: an updated review [J]. Eur J Dermatol, 2010, 20: 6-15. doi:  10.1684/ejd.2010.0833
    [9] Goudarzi M, Seyedjavadi S, Bagheri P, et al. Prevalence and genetic characteristics of fusidic acid resistant Staphylococcus aureus clinical isolates: Emergence of t030 strains carrying fusB in Tehran, Iran [J]. Acta Microbiol Immunol Hung, 2023, 70: 126-133. doi:  10.1556/030.2023.01997
    [10] Zhanel GG, Adam HJ, Baxter M, et al. In vitro activity and resistance rates of topical antimicrobials fusidic acid, mupirocin and ozenoxacin against skin and soft tissue infection pathogens obtained across Canada (CANWARD 2007-18) [J]. J Antimicrob Chemother, 2021, 76: 1808-1814. doi:  10.1093/jac/dkab098
    [11] Chen S, Rao L, Lin C. The Dissemination of Fusidic Acid Resistance Among Staphylococcus epidermidis Clinical Isolates in Wenzhou, China [J]. Infect Drug Resist, 2022, 15: 2537-2544. doi:  10.2147/IDR.S365071
    [12] Liu X, Deng S, Huang J, et al. Dissemination of macrolides, fusidic acid and mupirocin resistance among Staphylococcus aureus clinical isolates [J]. Oncotarget, 2017, 8: 58086-58097.
    [13] 胡付品, 郭燕, 朱德妹, 等. 2018年CHINET中国细菌耐药性监测[J]. 中国感染与化疗杂志, 2020, 20: 1-10. https://www.cnki.com.cn/Article/CJFDTOTAL-KGHL202001001.htm
    [14] 胡付品, 郭燕, 朱德妹, 等. 2020年CHINET中国细菌耐药监测[J]. 中国感染与化疗杂志, 2021, 21: 377-387. https://www.cnki.com.cn/Article/CJFDTOTAL-KGHL202205001.htm
    [15] 郑永贵, 胡付品, 朱德妹, 等. 2019年CHINET细菌耐药监测网二级医院监测结果[J]. 中国感染与化疗杂志, 2020, 20: 585-593. https://www.cnki.com.cn/Article/CJFDTOTAL-KGHL202006001.htm
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1239) PDF downloads(49) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return